Utility of Biparametric MRI (Magnetic Resonance Imaging) as a Screening Tool for Prostate Cancer in a High-Risk Cohort

Prostate Cancer Clinical Trial

Official title: Utility of Biparametric MRI (Magnetic Resonance Imaging) as a Screening Tool for Prostate Cancer in a High-Risk Cohort

Status Recruiting

Clinical Trial Summary

To determine whether using bpMRI in subjects who are at high risk of developing prostate cancer in conjunction with PSA will improve prostate cancer screening protocols.

Clinical Trial Description

The Investigators propose a pilot study which utilizes bpMRI in conjunction with PSA in the early detection of clinically significant prostate cancer in a high-risk group. Our study would focus on these high-risk subjects between the ages of 40-55 with a normal PSA ranging from ≥1.0 to <2.5 ng/mL. bpMRI would be obtained in this group of subjects. If any suspicious lesions are found, the recommendation is to undergo MRI/US fusion biopsy. Subjects with negative bpMRI will be followed every year with serum PSA. Subjects with a positive bpMRI will have a prostate fusion and systematic biopsy performed. Those with a benign biopsy will be followed every year with serum PSA. Those who have a biopsy positive for cancer will be managed and followed according to the standard of care. All subjects will be followed for 5 years. Our hypothesis is that bpMRI in conjunction with above average PSA in a high-risk group will increase detection of clinically relevant prostate cancer and provide a useful addition to PSA screening. ;

Related Conditions & MeSH terms

• Magnetic Resonance Imaging
• Population at Risk
• Prostate Cancer
• Prostatic Neoplasms

• NCT number: NCT05384535
• Study type: Interventional
• Source: Northwell Health
• Contact: Cynthia Knauer, RN
• Phone: 516-734-8500
• Email: urologyresearch@northwell.edu
• Status: Recruiting
• Phase: N/A
• Start date: August 15, 2022
• Completion date: October 31, 2026